Skip To The Main Content

PDA Comments: Viral Testing for Gene Therapies

Last December, PDA submitted comments to the U.S. FDA regarding Replication Competent Retrovirus (RCR) testing for gene therapy products.

You need to Login to view the full article. Please Login. Not a Member? Join today!
SHARE THIS ARTICLE
Advertisement

PDA Members Save Substantially